Viva Biotech Holdings has expanded its capabilities by strengthening its integrated pharmacology platform, enhancing its Drug Metabolism and Pharmacokinetics (DMPK), pharmacology, and efficacy services. The company has invested in facility expansion and deeper integration of antibody pharmacokinetics with disease-focused studies across multiple therapeutic areas. This comprehensive platform now supports a wide range of drug modalities, offering end-to-end services from structure-based discovery to IND filing and enabling more data-driven decisions in preclinical drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: CN54144) on December 29, 2025, and is solely responsible for the information contained therein.